



Ocrelizumab treatment pathway: a future direction

By Agne Straukiene ^{1a}, Finn Moxon ^{1b} Elizabeth Blackshaw ^{1c}, Sophie Maclean ^{1d}, Sarah Hughes ^{1e}

Introduction:

Disease Modifying Treatments (DMTs) are a large part of any MS services activity. These can take up a large part of any MSSN's workload and we identified operationally that we needed to change the use of our existing precious clinic appointment time to sustain the service. Ocrelizumab patients rarely reported new issues due to the high efficacy of their treatment, so they were identified as a target group as we had recently completed process mapping with the infusion unit (PIU) identifying areas of safe change



BACKGROUND:

- caseload 632 MS patients
- 50% on DMTs
- 23% on Ocrelizumab, being seen 6/12 by the MSSN to complete 2019 pathway & issue blood forms
- Appointments are allocated 40-minutes.
- Our caseload growth 4% pa.
- 1.0 WTE MSSN / 0.5 WTE Neurologist
- Documentation required impacts on MSSN time and departmental costs, not fully utilized on PIU

AIM:

We wanted to see if streamlining the process would:

- have positive impact on MSSN workload & use appointments more effectively.
- increase patient and staff satisfaction,
- Reduce ongoing Trust costs.
- Prescriptions completed quicker, no delays in infusions time
- Maintenance of patient safety.

CHANGES TO BE MADE:


- Redesign of pathway & use of existing Trust resources
- Blood and urine tests to be taken on day of infusion
- Instead of 6 monthly reviews are now annual reviews planned
- Monthly meetings between MSSN & PIU Senior Sister

METHODS:

- Change measurement at 2 time points: prior to and 9 months later of new pathway implementation
- Patients & staff surveys on experience / job satisfaction
- Qualitative analysis using a specifically created questionnaire as all patients should have had a minimum of one Ocrevus treatment during this time.
- Analysis of the current clinic templates before and after the new pathway implementation
- Early identification of any delayed infusions or events directly related to the infusion
- Analysis of Datix reporting

ACHEIVEMENETS SO FAR:

- Positive initial verbal feedback from patients when informed of upcoming changes
- PIU nurses initial response received
- Better working relationship and engagement between PIU & MSSN,
- Good clinical governance practice



Acknowledgements: All PIU staff and patients who have participated in the work to date.